Neumora Therapeutics opened lower at $0.47, compared with its previous close of $0.47. In the last trading session, the stock traded between $0.44 and $0.49. It showed a downward intraday trend.
An investment of $100 made 4 years ago in Neumora Therapeutics is now worth
$ 2.68
Resulting in a loss of
$ 97.32 (97.32%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.04 (-8.03%)
Day High
$0.49
Day Low
$0.44
Day Open
$0.47
Prev Close
$0.47
Volume
7,92,507
1W Return
-23.55%
1M Return
-0.91%
3M Return
-74.18%
6M Return
-76.74%
1Y Return
-84.18%
Market Cap ($ Mn)
82
PE Ratio
-
PB Ratio
5.79
PEG Ratio
-
ROE
-126.79%
ROCE
-117.59%
EPS (TTM)
$-0.23
1 Week
-23.55%
1 Month
-0.91%
3 Months
-74.18%
6 Months
-76.74%
9 Months
-85.50%
Neumora Therapeutics Q2 EPS of $(0.23) beats estimates
Neumora Therapeutics reported a Q2 net loss of $43.1 million, translating to an EPS of $(0.23) which beat the $(0.24) estimate. The per-share loss improved 30.3% YoY from $(0.33), supported by a drop in R&D spend to $29.3 million. The company holds $116.8 million in cash, sufficient for operations through Q3 2027.
3mo agoNeumora Therapeutics plans NMRA-215 IND filing in Q4 2026
Neumora Therapeutics has cleared a key safety hurdle for NMRA-215, reporting no unexpected adverse findings in a repeat 13-week rat toxicology study. This resolves issues from a prior audit where 5 of 142 animals showed adverse effects. With supportive data from dog and rat studies, the company will file an IND application in Q4 2026 to begin clinical trials for obesity and cardiometabolic disease.
3mo agoRBC Capital maintains Outperform on Neumora, cuts target to $5
RBC Capital analyst Brian Abrahams maintained an Outperform rating on Neumora Therapeutics but lowered the price target to $5 from $7. The adjustment reflects a revised valuation outlook for the NASDAQ-listed stock.
4mo agoMizuho maintains Outperform on Neumora, cuts target to $4
Mizuho analyst Graig Suvannavejh maintains an Outperform rating on Neumora Therapeutics (NASDAQ: NMRA) while lowering the price target from $6 to $4, adjusting the valuation outlook.
4mo agoLevi & Korsinsky investigates Neumora after trial failure
Levi & Korsinsky, LLP is investigating Neumora Therapeutics, Inc. regarding potential securities laws violations following the failure of the Phase 3 KOASTAL-2 and -3 trials for navacaprant. The firm is scrutinizing prior statements by leadership, including CFO Michael Milligan's cash runway projections and President Josh Pinto's guidance, which contrast with the subsequent discontinuation of the program and 35% staff reduction. Affected investors are encouraged to contact Joseph E. Levi, Esq. to discuss their legal rights.
4mo agoNeedham maintains Buy on Neumora, cuts target to $5
Needham analyst Ami Fadia maintained a Buy rating on Neumora Therapeutics but reduced the price target to $5 from $8.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 4 years ago in Neumora Therapeutics is now worth
$ 2.68
Resulting in a loss of
$ 97.32 (97.32%)
Note: Past profits do not guarantee future returns.
